Abstract Prion diseases are believed to propagate by the mechanism involving self-perpetuating conformational conversion of the normal form of the prion protein, PrP C , to the misfolded, pathogenic state, PrP Sc
Introduction
The existence of prion strains is one of the most controversial and poorly understood facets of prion diseases. The concept of strain, borrowed from virology, was introduced to the field of prion diseases at the time when it was believed that these disorders, known as transmissible spongiform encephalopathies, were caused by viruses or other infectious agents yet to be identified. The idea that prion diseases can be associated with different strains of the infectious agent emerged from the observation that animals inoculated with brain homogenates from different scrapie-infected donors consistently developed a disease with distinct incubation times and histopathological lesions, and these differences could be stably propagated in subsequent passages into syngenic hosts. More recently, the apparent analogy between strain phenomena in viruses and prion diseases has been pushed even further with the demonstration that prion strains can undergo apparent mutations and selective amplification, which may lead to drug resistance [43] .
While such phenomena are easily explained for viruses carrying nucleic acid that confers upon them the propensity to mutate and undergo selection, the existence of different prion strains has for many years presented a major challenge to the protein-only hypothesis of prion diseases. The latter model asserts that the infectious pathogen is not a virus but a misfolded form of the prion protein, PrP Sc , which self-perpetuates by a mechanism that entails binding to the normal prion protein, PrP C , and inducing its conversion to the PrP Sc state. A series of recent studies has provided conclusive evidence in support of this proteinonly hypothesis [14, 32, 41, 45, 73] . Within the context of this model, prion strains are believed to be encrypted in distinct conformations of PrP
Sc . This conformational diversity may arise from a number of factors, including the amino acid sequence of substrate PrP C , the cell and tissue environment where the conversion takes place, and the process leading to the selection of the successful strain from the PrP Sc population initially engendered [12] .
Human prion diseases: heterogeneity
The issue of strains is of particular significance in the case of human prion diseases for the ultimate cause of the extraordinary diversity of these disorders which may lie in strain variability (Tables 1, 2 ). Human prion diseases are unique in that they may be acquired by infection, be inherited, or arise spontaneously. The critical initial event in the pathogenesis of the form acquired by infection is the interaction between the exogenous PrP Sc and the endogenous PrP C of the recipient. This interaction results in the formation of endogenous PrP Sc which propagates further by autocatalytic conversion of additional PrP C molecules, while the original exogenous PrP Sc is cleared. The physicochemical characteristics of the exogenous PrP Sc , the site of the initial conversion, and the tissues and organs involved on the pathway toward brain invasion are among many factors that may contribute to strain variability of the acquired cases. In the inherited prion diseases, the presence of a mutation is thought to alter the properties of PrP C , promoting its conversion to the PrP Sc state [37] . The combination of specific mutation with the methionine/ valine (M/V) polymorphism at codon 129 is the major determinant of strain variation in familial cases [20] . The nature of the etiological events which lead to the idiopathic or sporadic form of prion diseases is less clear. Several scenarios, not mutually exclusive, have been proposed as explanations for the initial PrP C misfolding and PrP Sc formation. One scenario posits an error in PrP post-translational processing, or the occurrence of a somatic mutation coupled with a weakening in the stringency of the quality control system which is known to occur in aging [21, 33, 60] . Another scenario presupposes the presence of PrP Sc -like oligomers (denoted PrP * or silent prions) under normal conditions [75] . Following accidental stabilization likely facilitated by aging, PrP * would acquire the capability to convert PrP C to PrP Sc , thereby triggering the disease [15] . Regardless of the etiology, all the three forms of prion disease present a remarkable degree of phenotypic heterogeneity, which is likely to be closely related to the diversity of prion strains.
History of human prion strains
The very first evidence of diversity in human prion strains was reported in 1992 in a study describing the linkage of the D178N PrP gene mutation (leading to the substitution of aspartic acid with asparagine at PrP position 178) to a phenotype named fatal familial insomnia (FFI) [44, 46, 47] . It was observed that the PrP Sc associated with FFI is characterized by an electrophoretic mobility different from that of PrP Sc in sporadic CJD (sCJD) [47] . Subsequent studies described the linkage of the D178N mutation not only to FFI but also to yet another CJD-like phenotype, which was identified as familial (f) CJD D178N [20] . These two phenotypes were found to co-segregate with the genotype of codon 129 present in the mutated allele: FFI was associated with the methionine codon (129M), whereas fCJD D178N segregated with the valine codon (129V) (Fig. 1) [20] . Therefore, while the D178N mutation may trigger the disease, codon 129 on the mutated allele appears to determine the basic characteristics of the disease phenotype. These observations provided the first evidence that the 129M/V polymorphism plays an important role in determining the prion disease phenotype. Furthermore, immunoblot examination demonstrated that the proteaseresistant PrP Sc in the two conditions had distinct electrophoretic mobilities: in FFI the unglycosylated form of the protease-resistant PrP Sc had an electrophoretic mobility of 19 kDa, whereas in fCJD D178N the corresponding mobility was approximately 21 kDa. These two PrP Sc conformers were subsequently named types 1 (the 21 kDa) and type 2 (the 19 kDa) (Fig. 1) [48, 55] .
The FFI, along with sCJDMM1 and fCJD E200K , were then transmitted to transgenic (Tg) mice expressing chimera human/mouse PrP with 129M (fCJD D178N could not be transmitted likely because of the mismatch in the 129 residue with the Tg mouse PrP) (Fig. 1) . The PrP Sc in these infected mice faithfully reproduced electrophoretic mobilities of the inoculum (i.e., 19 kDa in FFI and 21 kDa in fCJD E200K and sCJDMM1), and these characteristics were maintained upon second passage [38, 71] . Furthermore, the pattern of PrP Sc deposition in the brain was also different in the affected mice inoculated with brain homogenates from FFI, sCJDMM1, or fCJD
E200K
. These findings clearly indicate that the PrP Sc isoforms associated with FFI and fCJD E200K are distinct, representing stable prion strains which can be reproduced even in the absence of the original PrP gene mutations in the host animals.
The realization that the polymorphic codon 129 of the PrP gene could modify the phenotype of familial prion diseases raised the question as to whether the 129 genotype could also affect the phenotype in sporadic prion diseases and thereby explain, at least in part, the phenotypic heterogeneity of these diseases. Cases with proven sCJD were then subdivided into six groups according to the six possible combination of their PrP Sc type (either 1 or 2) with each of the three possible 129 genotypes (MM, MV, or VV). The phenotypes of the six possible combinations were examined for homogeneity within the group and diversity between groups. This exercise led to a new classification of sporadic prion diseases based on molecular rather than clinical or histopathological features, making possible the identification of six distinct phenotypes of sporadic prion disease (Table 2) [17, 55, 56] . The first and most common phenotype is associated with both the 129MM and 129MV genotypes and with PrP Sc type 1 [sCJDMM(MV)1]; it is often referred to as ''classic'' CJD. The second and third phenotypes associated with sCJDVV1 and sCJDMM2 had not been identified as separate subtypes in previous clinical or pathological classifications. The sCJDMM2 phenotype is characterized by the very large and often confluent vacuoles of the spongiform degeneration (SD), whereas the frequently early age at onset defines sCJDVV1. The two phenotypes labeled sCJDMV2 and sCJDVV2 match the phenotype previously labeled as cerebellar or ataxic. Despite their similar clinical features, these two phenotypes can easily be distinguished by the presence in the cerebellum of kuru-like plaques in sCJDMV2 (but not in sCJDVV2) and their different patterns of cerebellar PrP immunostaining. The sixth phenotype is associated with sFI. This phenotype is virtually indistinguishable from that of FFI and matches the sCJD form previously identified as thalamic. This classification goes a long way toward Table 2 ).
An alternative classification of PrP Sc types and their pairing with CJD phenotypes has been proposed by Collinge and collaborators [11, 26, 42] . This classification differs from that of Parchi and colleagues discussed above in two major aspects: (1) It recognizes three (not two) PrP Sc types based on electrophoretic mobility and (2) it proposes the same nomenclature, i.e., with progressive PrP Sc type numbers, also for PrP Sc isoforms with different ratios of the three PrP glycoforms. In the classification by Parchi and coworkers, PrP Sc types 1 and 2 that show different glycoform ratios are differentiated with letters (Fig. 2) . Including variant CJD, six human PrP Sc types have been identified according to Collinge and colleagues. As for the associations with the sCJD phenotypes, PrP Sc type 1 would be present in a subtype characterized by a slightly shorter disease duration, which includes sCJDMM and sCJDMV; types 2 and 3 would be found in all three 129 genotype in cases generally of long duration. However, the PrP Sc electrophoretic profile in sCJDMM3 and sCJDVV3 apparently differed from that of sCJDMV3.
The studies on classification of sporadic prion diseases and PrP Sc typing also provided insight into the relationship between the 129 genotype and the PrP Sc type. In the original study of Parchi et al. [17, 56] over 95% of cases homozygous for methionine at codon 129 (129MM) were Sc from fCJD D178N . The red square represents the conformation of PrP Sc from fCJD E200K , which although being type 1 as fCJD D178N -associated PrP Sc , is presumably different based on the fCJD E200K distinct phenotype found to be associated with PrP Sc type 1, while 86% of sCJD cases associated with PrP Sc type 2 were found to be homozygous for valine or methionine/valine heterozygous (129VV and 129MV). Therefore, the 129MM genotype appears to favor the formation of PrP Sc type 1, whereas type 2 formation is favored by the presence of one or two 129V alleles. The study of the recently discovered cases of sCJD that actually carries both types 1 and 2 further support this notion (Table 3 and see below) [7, 59] .
Furthermore, amino acid sequencing has revealed that while the major N-termini of PrP Sc types 1 and 2 are at residue 82 and 97, respectively, secondary N-termini are present in both PrP Sc types 1 and 2 ( Fig. 3 ) [58] .
Interestingly, the secondary N-termini appear to be nonrandom but rather to correlate with the PrP Sc types and the 129 genotype. They show three main characteristics. First, they are more prevalent in PrP Sc type 2 than in type 1. Second, within each PrP Sc type, secondary cleavages are more prominent in the 129MV heterozygous than homozygous 129 genotypes. Third, they appear to be distributed toward opposite directions in the PrP sequence: in PrP Sc type 1 they appear to involve to a greater extent the PrP sequence that is C-terminal to the main cleavage site, whereas in PrP Sc type 2 they extend more toward the region that is N-terminal to the main cleavage site (Fig. 3) . Therefore, the 129 genotype may affect not only the main cleavages of the protease resistant fragments of PrP Sc types 1 and 2 but also the number of the secondary cleavages and, therefore, the degree of conformational heterogeneity within each PrP Sc type. Altogether, available data strongly suggest that PrP Sc type formation and finer variations within each type are influenced by the genotype at codon 129.
Residue 129 polymorphism and strain determination: a biophysical perspective
The fundamentally important role of M/V polymorphism at codon 129 in human PrP C prompted studies aimed at understanding the effect of this polymorphism on the structure and biophysical properties of the recombinant prion protein. However, extensive NMR and X-ray crystallographic studies have failed to detect any significant differences in the global and local protein fold between the 129M-and 129V-containing structures [27, 40] . Furthermore, residue 129M/V polymorphism was found to have no measurable effect on the global thermodynamic stability, folding, or dynamics of the PrP monomer [27] . These findings suggest that the effect of residue 129 on prion diseases is mediated by events taking place at the time of PrP Sc formation, events which probably influence the conformation of the PrP Sc oligomer [27] . Consistent with this view, structural differences which were dependent upon polymorphism were detected by FTIR spectroscopy for amyloid fibrils formed by recombinant PrP90-231 [2] and recombinant PrP23-144 [30] . An interesting insight into the potential nature of these structural effects was provided by recent crystallographic data for six-residue segments of PrP centered on residue 129. These studies revealed that the crystal structures for M-and V-containing peptides differ in packing within the socalled 'steric zipper' motif [3] . It was suggested that these packing effects could account for differences in disease susceptibility between individuals who are homozygous or heterozygous for either 129M or 129V [3] . However, it is not known whether the structures of these short segments adequately represent structural features within the corresponding region of PrP Sc . The effect of 129 polymorphism on the structure and biophysical properties of PrP has also been explored in the context of the pathogenic mutation D178N. From early NMR measurements, it was inferred that, in wild-type PrP, Asp178 forms a salt bridge with Arg164 and has the potential to form a hydrogen bond with Tyr128, a residue sequentially adjacent to position 129 [65] . It was also proposed that the Asp ? Asn replacement at position 178 would affect this network of hydrogen bonds differentially, depending on residue 129 Met/Val polymorphism, providing a rationale for polymorphism-dependent phenotypic variability of inherited prion diseases with D178N mutation. A more detailed insight into structural effects of D178N mutation was provided by recent crystallographic data, which revealed mutation-dependent differences in the loop region (residues R164-S170), as well as polymorphism-dependent differences in the local environment surrounding the altered D178N residue [40] . It was also shown that the polymorphism at residue 129 strongly affects conversion of the D178N variant of recombinant PrP to amyloid fibrils, with the 129M polymorph undergoing substantially faster conversion than the 129V polymorph [2] . Furthermore, fibrils formed by the D178N/ 129V variant appear to be structurally distinct from those formed by the D178N/129M protein [2] . Altogether, this biophysical insight strongly suggests that, by modulating both the conversion process and the conformation of PrP Sc , residue 129V/M polymorphism governs susceptibility to prion disease and prion strain properties.
Prion strains in human prion diseases
Sporadic prion diseases: Creutzfeldt-Jakob disease and fatal insomnia From the perspective of the disease, prion strains may be viewed as PrP Sc conformers which often (but not necessarily always) are associated with distinct disease phenotypes [4, 6, 11, 61, 68, 71] . Within the context of this definition, PrP Sc types 1 and 2 definitely fulfill the requirements of distinct prion strains for several reasons. First, they have different physicochemical characteristics such as proteolytic cleavage sites and conformational stability profiles, the features implying different conformations [8, 10, 36, 51, 58] . Second, upon inoculation, they cause diseases characterized by different incubation times, histopathologies, and PrP Sc distributions [5, 38, 49, 69, 70] . Finally, they can be faithfully replicated by protein misfolding cyclic amplification (PMCA) [9, 31, 67] . However, the identification of six phenotypes, five in sCJD and one in sFI (according to the classification of Parchi and colleagues [56] ), raises the question of the number of distinct strains of sCJD [17] . Distinctive clinical, histopathological, and PrP immunostaining features of the six phenotypes point to an association with at least six distinct PrP Sc strains. Should this be the case, the strains of sporadic prion diseases would far exceed types 1 and 2. This implies that PrP Sc types 1 and 2, rather than just representing two strains, actually define two categories of strain subtypes, each associated with a distinct phenotype.
Several studies of sCJD subtypes, including transmission to transgenic mice expressing human PrP C or chimera human/mouse PrP, have been reported in the last 15 years [11, 25, 35, [70] [71] [72] . These studies provide strong evidence that some sCJD subtypes are indeed associated with distinct PrP Sc strains. However, only one recent study has systematically attempted to determine the number of PrP Sc strains associated with the major subtypes of sCJD [5] .
Bishop et al. [5] tested the strain characteristics of PrP Sc isoforms associated with sCJD (but not sFI) by inoculating sCJD brain homogenates representing the six possible combinations of the 129 genotype and PrP Sc type (i.e., MM, MV, and VV each associated with PrP Sc 1 or 2) into knock-in Tg mice expressing human PrP C with each of the three 129 genotypes. Using incubation times, lesion profiles, and the pattern of PrP Sc intracerebral deposition, this study identified four strains and found them to be associated with the five phenotypes identified in sCJD by Parchi et al. [5, 56] Sc is cleaved at the more C-terminal residues 90 and 97, the latter being the major cleavage site of PrP Sc type 2 [58] . Although additional sCJDMV1 cases need to be examined, these extra cleavage sites argue for the presence of a small amount of PrP Sc type 2 in MV1PrP Sc . A second consideration suggested by the data of Bishop and colleagues is that although by bioassay MV2PrP
Sc and VV2PrP
Sc were found to have identical strain features, the clinical and pathological differences between sCJDMV2 and sCJDVV2-the two phenotypes to which they are associated-suggests otherwise. Major neuropathological differences occur in the cerebellum, where in the case of sCJDMV2 PrP Sc kuru plaque-like deposits with the tinctorial characteristics of the amyloid are found along with good preservation of neurons [16, 17, 55, 56] . In contrast, in sCJDVV2, the PrP deposits are loose and amyloid-free, and there is a significant loss of neurons. These contrasting features argue that the mode by which the PrP Sc aggregates form and possibly the toxicity associated with these aggregates differ in these two sCJD subtypes. Consistent with the presumed higher toxicity of the PrP Sc aggregates in sCJDVV2, the clinical duration of the disease is also significantly shorter in this sCJD subtype (6.5 months with a 3-18-month range compared with 17 months with a 5-72-month range in sCJDMV2) [12, 56] . According to a recently proposed model of strain pathogenicity, the diverse features that distinguish sCJDMV2 from sCJDVV2 could result from different kinetics of PrP Sc propagation [12] . Furthermore, sequencing has shown that the N-terminus of PK-resistant core of MV2PrP
Sc is somewhat more ragged than that of VV2PrP
Sc . The presence in MV2PrP
Sc of a fragment starting at residue 82, the major cleavage site of PrP Sc type 1, is consistent with the presence of small amounts of PrP Sc type 1 [58] . In agreement with this finding, the electrophoretic profiles of MV2PrP
Sc from most brain regions are easily distinguished by the presence of two highly PK-resistant bands (corresponding to the unglycosylated isoform) in the MV2PrP Sc blot profile and only one such band in the profile of VV2PrP
Sc [50, 51, 59] . Furthermore, the electrophoretic profile of VV2PrP
Sc shows an additional fragment of approximately 18 kDa [59] . These findings suggest that, although not distinguishable after transmission to receptive animals, the MV2PrP
Sc and VV2PrP Sc isoforms behave differently in the human brain. Distinct physicochemical features may be revealed upon more extensive examination.
The poor transmissibility of both MM2PrP Sc and VV1PrP
Sc to Tg mice of all three 129 genetic backgrounds sets these two strains apart, suggesting that they form differently from the other sCJD strains. According to a prevailing hypothesis, the primary structure of the host's PrP C determines the spectrum of PrP Sc conformations that can be generated in a given species [12, 29, 43] . However, it is likely that several distinct isoforms of PrP Sc are initially generated when PrP C converts to PrP Sc . The successful strain is viewed as the result of a selection dictated by the extent to which the rate of conversion and propagation exceeds the rate of clearance for that particular PrP isoform [12] . According to this hypothesis, VV1PrP
Sc and MM2PrP
Sc might represent isoforms which under some exceptional conditions 'escape' the selection process. This would explain the extreme rarity of these strains (sCJDMM2 and sCJDVV1 combined account for only *3% of all cases of sCJD [25, 56] ) as well as the difficulty encountered in replicating them in humanized Tg mice regardless of the 129 background [5] .
Finally, it is noteworthy that neither the study of Bishop et al. [5] nor any other study on sCJD transmission to humanized Tg mice has found the PrP Sc type 1 described by Collinge et al. [11] (that displays a slightly slower gel mobility than the PrP Sc type 1 described by Parchi et al. [56] ).
Sporadic CJD with co-occurrence of PrP res type 1 and type 2 It has now been clearly established that, although sCJD subtypes exclusively associated with PrP Sc type 1 or type 2 account for the majority of the cases, the concurrent presence of both PrP res types is significant, varying between 15 and 43% according to the sCJD 129 genotype (Table 3) [7, 22, 42, 59, 64, 69, 72] . The co-occurrence of PrP res types 1 and 2 (hereafter identified as type 1-2) seems to follow certain general patterns. The two PrP res types can be found together in the same brain region or separately in different regions. Regardless of whether combined or separate, the topographic distribution of PrP res 1-2 is nonrandom: it favors specific brain regions such as the cerebral neocortex and the thalamus, but is less common in the cerebellum. Therefore, every brain region can contain both PrP Sc types though some regions, such as the thalamus, appear to be more apt to propagate both PrP Sc types [7, 59] . Again, the representation of types 1 and 2 appears to correlate with the 129 genotype; in sCJDMM1-2 type 1 dominates, whereas in sCJDMV and sCJDVV the opposite is observed, indicating that the strong association of PrP Sc type 1 with the 129MM homozygosity and of PrP Sc type 2 with the presence of at least one 129V allele is also maintained in sCJD1-2 [56, 59] . In general, the concomitant presence of PrP Sc types 1 and 2 has the tendency to modify the clinical and histopathological phenotype which exhibits features that are intermediate between the phenotypes associated with the corresponding sCJD1 and sCJD2 variants [7, 59] . This is particularly noticeable in the sCJDMM group, in which case the shift of the phenotype from sCJDMM1 to sCJDMM2 is directly related to the amount of PrP Sc type 2 present in the brain [7] . The PrP Sc type-related shift of the phenotype is much less noticeable for sCJDMV1-2 and sCJDVV1-2, perhaps because the presence of one or two 129V alleles makes the phenotypic features of sCJDMV2 and sCJDVV2 dominant over those of sCJDMV1 and sCJDVV1 [19] . Additional studies are needed to more clearly define the phenotype and PrP Sc characteristics of sCJDMV1-2 and sCJDVV1-2 [19, 59] . With regard to PrP Sc strain characteristics in sCJDMM1-2, it is intriguing that the co-existence of PrP Sc types 1 and 2 in the same brain locale seems to alter the characteristics of each of the two PrP Sc types compared to those displayed when they occur separately. For example, the resistance to denaturation of PrP Sc type 1, as determined by the conformation stability immunoassay (CSI), becomes similar to that of PrP Sc type 2 although the cleavage sites of the shifted PrP Sc do not change (Fig. 4) . A similar effect is also seen after PrP Sc types 1 and 2 are mixed in vitro [7] . Therefore, types 1 and 2 co-occurrence in vivo, as well as the interaction of the two types in vitro, may change some conformational characteristics of PrP Sc type 1 [7] . These findings suggest yet another potential mechanism of strain mutation [1, 12, 43] . On the whole, the co-occurrence of PrP Sc types 1 and 2 is likely to shed light on the effect that co-occurring strains may exert upon one another as well as on the selection process leading to the presence of two major strains [1, 7] .
Sporadic fatal insomnia (also occasionally referred to as sCJDMM2 thalamic) It presents a special challenge in the assessment of prion strains associated with sporadic prion diseases. Although the clinical and histopathological phenotypes of sFI and sCJDMM2 are quite distinct, both conditions are associated with the 129MM genotype and PrP Sc type 2 [56] [57] [58] . A most striking variation between these two diseases lies in their contrastive lesion topography. In sFI, the thalamus is very severely affected, and the cerebral cortex is often almost spared, while the opposite is true for SCJDMM2. This suggests that the histopathology starts, and the pathogenic PrP Sc initially acts, in different brain regions. The lack of correlation of the phenotype with the 129 genotype and the PrP Sc type in these two diseases raises questions regarding the role and nature of additional factors (beyond the 129 genotype and PrP Sc type) as potential determinants of prion strains.
A possible feature distinguishing PrP Sc conformers associated with sFI and sCJDMM2 is the pattern of glycosylation as revealed by two-dimensional WB analysis [54] . Whether differences in glycosylation can explain variations in the phenotype remains, however, to be determined [8, 63] . Furthermore, variations in the PK-resistant PrP GdnHCl (M) Fig. 4 Conformation stability immunoassay (CSI) of the unglycosylated isoform of PrP Sc from sCJDMM1, sCJDMM2, and sCJDMM1-2. To measure the stability of PrP Sc , increasing concentrations of GdnHCl are used to unfold PrP Sc , which in turn becomes progressively more sensitive to digestion with PK. The concentration of guanidine applied to achieve the digestion of 50% of the PrP Sc with proteinase K (PK) is indicated by [GdnHCl] 1/2 (vertical color-coded broken lines). The CSI curve shows that the stability of the PrP Sc type 1 when it is present alone as in sCJDMM1 (red hollow diamond) is significantly different from the stability that it shows when it cooccurs with PrP Sc type 2 as in sCJDMM1-2 (green solid triangle)
). Furthermore, the CSI curve of the PrP Sc type 1 from sCJDMM1-2 becomes indistinguishable from that of PrP Sc type 2 from sCJDMM2 (black square with hollow circle) and sCJDMM1-2 (blue solid circle), which are similar indicating no change in CSI characteristics between PrP Sc 2 when alone or co-occurring with type 1. CSI profiles are smooth curves best matching data (mean ± SD) obtained at different concentrations of guanidine fragments associated with sFI and sCJDMM2 have been reported [52] .
Atypical prion diseases: variably protease-sensitive prionopathy
A disease affecting the prion protein but exhibiting characteristics different from those of the classic prion diseases was first reported in 2008 [18] . The study of 11 original cases revealed several major features which distinguished this disorder from common sporadic prion diseases. These include the relatively long duration of nearly 2 years, clinical presentation more consistent with that of an atypical dementia than sporadic prion disease, the distinctive ladder-like electrophoretic profile, and relatively low protease-resistance of the insoluble, disease-associated PrP (PrP Dis ) (Fig. 2) . Due to these characteristics as well as the uncertainty regarding transmissibility, this condition was originally named ''protease-sensitive prionopathy''. Another peculiar feature of this condition is that six out of ten cases that could be investigated had a positive family history of cognitive impairment. However, none of these cases was associated with a mutation in the open reading frame of the PrP gene.
All the 11 cases of the original report were 129VV. However, a subsequent study revealed that the same disease also affects subjects with the 129MV and 129MM genotypes, and the disease was renamed ''variably protease-sensitive prionopathy'' (VPSPr) (see below) [77] . Currently, 29 cases of VPSPr have been reported: 20 are 129VV, 6 are 129MV, and 3 are 129MM [18, 23, 28, 39, 77] . Thus, after the original report of CJD in 1921, VPSPr appears to be the second presumably sporadic disease involving the prion protein that affects all the three 129 genotypes [34] .
The finding that VPSPr affects the three 129 genotypes raises a number of intriguing questions. One of them is whether each 129 genotype is paired with a distinct phenotype and distinct PrP Dis characteristics as is the case with subtypes of sCJD [17, 56] . Clinically the 129VV and 129MV VPSPr cases (the availability of only two 129MM symptomatic cases precludes the comparative clinical study of this subset) differ significantly in duration and the prevalence of myoclonus. Though histopathologically these cases differ only slightly with respect to PrP immunostaining patterns, the major difference lies in the PK resistance of PrP Dis [77] . As originally reported, PrP
Dis from 129VV cases is very sensitive to PK digestion, whereas the PK-resistance of PrP Dis from 129MM cases is comparable to that of PrP Sc in classic prion diseases, and the proteolytic resistance of 129MV cases lies somewhere between those of 129 MM and 129 VV cases. This variability in PK resistance that co-distributes with the 129 genotype prompted the addition of ''variably'' to the original label of ''protease-sensitive prionopathy'' [77] . Furthermore, although the ladder-like electrophoretic profile is shared by all three VPSPr 129 genotypes, the ratios of the individual bands are different, suggesting that though the same PrP Dis sites are cleaved by PK their accessibility is dissimilar. Finally, the PrP Dis conformers associated with the three VPSPr genotypes also differ in the degree of immunoreactivity with monoclonal antibodies 3F4 (epitope within residues 106-110) and 1E4 (epitope within residues 97-105) [76, 78] . Although these variations may not be as distinctive as they are between the subtypes of sCJD, the three 129 genotypes of VPSPr are associated with distinguishable phenotypes and PrP Dis characteristics. Of note, there appears to be a drastic difference between VPSPr and classic prion diseases with respect to the prevalence of the three 129 genotypes. In VPSPr, the 129MM, 129MV, and 129VV genotypes account for 10, 23, and 67% of all cases, respectively. In contrast, 129MM, 129MV, and 129VV patients account for 72, 11, and 17%, respectively, of all sCJD and sFI cases combined [17, 24, 56] . Furthermore, in VPSPr, as well as in sCJD, the representations of the three 129 genotypes markedly differ from the prevalence of these genotypes in the general Caucasian population [53] . In sCJD, the overrepresentations of the 129MM and (to a lesser extent) the 129VV genotypes, combined with the underrepresentation of the 129MV genotype, have been attributed to more efficient conformational conversion of PrP C to PrP Sc in individuals homozygous at codon 129 compared to those heterozygous at this codon [3, 53] . This mechanism does not seem to play a role in VPSPr, in which the 129VV genotype appears to pose by far the highest risk, whereas the 129MM genotype appears to be protective.
Altogether, available data argue that PrP Dis associated with VPSPr is distinct from the PrP Sc strains associated with the various subtypes of sCJD, and that the 129 genotype may play a different role in PrP Dis formation [18] . Furthermore, the distinctive phenotypic and PrP Dis features observed among the three 129 genotypes suggest that PrP Dis types associated with these genotypes represent distinct strains (or, at least, substrains according to the recently proposed terminology [13, 74] ). More detailed characterization of these strains awaits the results of ongoing studies on amplification and transmissibility.
Conclusion
The assessment of the number of strains associated with human sporadic prion diseases must take into account the observation that both the 129 genotype and the PrP Sc type are the major determinants of the disease phenotype.
However, the role of these two determinants is complex and interrelated. First, the genotype at codon 129 appears to be a major determinant of PrP Sc types 1 and 2 which, in turn, are also associated with different phenotypes. However, the three 129 genotypes also may act as determinants of the phenotype in the sCJD associated with PrP Sc types 1 as well as type 2. Since there are three 129 genotypes and two PrP Sc types, one would expect that, at least theoretically, up to six distinct strains could be associated with sCJD and sFI combined, each of them corresponding to one of the six possible pairings of three codon 129 genotypes with the two PrP Sc types. However, as discussed in this article, there might be a number of exceptions to this general scenario.
First exception is exemplified by sCJDMM1 and sCJDMV1. Despite the different 129 genotype, these two subtypes of sCJD share the same phenotype and appear to be associated with same strain, suggesting that the 129V allele plays no role in determining the phenotype or the PrP Sc characteristics in sCJDMV1. The opposite exception is sCJDMM2 and sFI, which, despite being associated with two very different phenotypes, share the same combination of 129MM genotype and PrP Sc type 2. Although the mechanism of phenotypic determination in these two diseases is currently unknown, it is reasonable to expect that specific features which discriminate between the two PrP Sc strains associated with sCJDMM2 and sFI do exist and will eventually be found.
Another layer of complexity arises from the inability of propagating to receptive mice the distinct strain properties apparently exhibited by the PrP Sc conformers associated with sCJDMV2 and sCJDVV2 [5] . Again, although the phenotype-determining characteristics of some strains are apparently evident in the human disease, they might be difficult to propagate experimentally, perhaps because of their instability.
Yet, another interesting situation is presented by sCJDVV1, in which PrP Sc appears to have all the features of a distinct strain. However, sCJDVV1, like sCJDMM2 and sFI, has a very low prevalence and, like sCJDMM2, is difficult to transmit to humanized Tg mice [5] . Therefore, the strains associated with these three phenotypes are unusual. They might represent variant strains which have escaped the selection process believed to occur during strain formation [12] .
Altogether, the picture emerging from these considerations suggests that despite the exceptions previously noted, there are at least six different strains associated with sCJD and sFI, three of which are common while the other three are rare or variant strains (Fig. 5) .
Despite recent progress in strain-dependent characterization of sporadic human prion diseases, there are still a number of unresolved questions. Can the presumed strains associated with sCJDMM2 and sFI be distinguished based on their physicochemical properties? What mechanism governs the reciprocal influence of PrP Sc types 1 and 2 when they co-occur in sCJDMM1-2? Are some strains inherently unstable and, thus, unable to propagate some of their phenotype-determining characteristics upon transmission? Does PrP Dis associated with VPSPr qualify as a true strain which encompasses three distinguishable substrains? Clearly, additional studies are needed to dissect the intricate details of human prion strains. Such studies have potentially broader implications, for recent data suggest that the strain phenomenon may also be relevant to other neurodegenerative diseases associated with protein misfolding and aggregation [62, 66] Sc type combinations with the phenotypes is not stringent. Notable exceptions are the association of the distinct MM1 and MV1 combinations with one phenotype (MM1/ MV1) and the association of the single MM2 combination with two phenotypes (MM2 sCJD and MM2 sFI). It is proposed that the six phenotypes are paired with six distinct prion strains, three of which are relatively prevalent, while three are rare and might result from variations in the strain selection process. The distinct strain proposed to be associated with sCJDMV2 is questionable because of the inability to maintain its distinctive characteristics after transmission [5] . Coexistence of types 1 and 2 associated with the three 129 genotypes and the strains possibly associated with the novel disease variably protease-sensitive prionopathy (VPSPr) are not shown for simplicity and because the presence of true strains in VPSPr is currently unclear
